|
業務類別
|
Drug Manufacturers - Specialty & Generic |
|
業務概覽
|
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. |
| 公司地址
| 555 Long Wharf Drive, New Haven, CT, USA, 06511 |
| 電話號碼
| +1 475 238-6837 |
| 傳真號碼
| +1 475 238-6837 |
| 公司網頁
| https://www.bioxceltherapeutics.com |
| 員工數量
| 29 |
| Mr. Richard I. Steinhart |
Senior Vice President, Chief Financial Officer and Principal Accounting Officer |
美元 409.87K |
27/03/2026 |
| Dr. Vimal Mehta, PhD |
Director, Chief Executive Officer and President |
美元 1.00M |
27/03/2026 |
| Dr. Frank D. Yocca, PhD |
Senior Vice President and Chief Scientific Officer |
-- |
27/03/2026 |
| Mr. Javier Rodriguez |
Senior Vice President, Chief Legal Officer and Corporate Secretary |
美元 423.83K |
27/03/2026 |
|
|
| Mr. Michael Miller |
Independent Director |
27/03/2026 |
| Dr. Peter Mueller,PhD |
Chairman of the Board |
27/03/2026 |
| Dr. Michal Votruba, M.D.,PhD |
Independent Director |
27/03/2026 |
| Dr. Sandeep Laumas, M.D. |
Independent Director |
27/03/2026 |
| Dr. Vimal Mehta, PhD |
Director, Chief Executive Officer and President |
27/03/2026 |
| Ms. June Bray |
Independent Director |
27/03/2026 |
| Mr. David J. Mack |
Independent Director |
27/03/2026 |
| Dr. Rajiv Patni, M.D. |
Director |
27/03/2026 |
|
|
|
|
